Healthcare -
Drug Manufacturers - General - NYSE - US
$ 150.62
-1.71 %
$ 363 B
Market Cap
26.01
P/E
1. INTRINSIC VALUE
Balance Sheet
Johnson & Johnson
| Current Assets | 55.9 B |
| Cash & Short-Term Investments | 24.5 B |
| Receivables | 18.9 B |
| Other Current Assets | 12.4 B |
| Non-Current Assets | 124 B |
| Long-Term Investments | 0 |
| PP&E | 21.6 B |
| Other Non-Current Assets | 103 B |
| Current Liabilities | 50.3 B |
| Accounts Payable | 10.3 B |
| Short-Term Debt | 5.98 B |
| Other Current Liabilities | 34 B |
| Non-Current Liabilities | 58.3 B |
| Long-Term Debt | 30.7 B |
| Other Non-Current Liabilities | 27.6 B |
EFFICIENCY
Earnings Waterfall
Johnson & Johnson
| Revenue | 88.8 B |
| Cost Of Revenue | 27.5 B |
| Gross Profit | 61.4 B |
| Operating Expenses | 39.2 B |
| Operating Income | 22.1 B |
| Other Expenses | 8.08 B |
| Net Income | 14.1 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Johnson & Johnson
| Net Income | 14.1 B |
| Depreciation & Amortization | 7.34 B |
| Capital Expenditures | -4.42 B |
| Stock-Based Compensation | 1.18 B |
| Change in Working Capital | 1.84 B |
| Others | 3.78 B |
| Free Cash Flow | 19.8 B |
Wall Street Analysts Price Targets
Johnson & Johnson
Wall Street analysts predict an average 1-year price target for JNJ of $172 , with forecasts ranging from
a
low of
$150 to a high of $215 .
JNJ Lowest Price Target
Wall Street Target
150 USD
-0.41%
JNJ Average Price Target
Wall Street Target
172 USD
14.15%
JNJ Highest Price Target
Wall Street Target
215 USD
42.74%
4. DIVIDEND
ANALYSIS
0.86%
DIVIDEND YIELD
1.24 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Johnson & Johnson
Sold
0-3 MONTHS
3.23 M USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
930 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
147 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
zacks.com
- 1 week ago
European Commission approves Johnson & Johnson's subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting
globenewswire.com
- 1 week ago
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (April 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. The market is volatile with economic uncertainties, but investing consistently in solid dividend-paying stocks with reasonable valuations is a good idea. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.
seekingalpha.com
- 2 weeks ago
4 of Wall Street's Most Beloved Blue-Chip Dividend Stocks Are Sale-Priced April Bargains
Large-capitalization blue-chip dividend stocks are a favorite among investors for a good reason.
247wallst.com
- 2 weeks ago
4 Blue Chip Pharmaceutical High-Yield Dividend Stocks Are Tariff Winners
With some pharmaceutical stocks paying 4% and higher dividends, they may be the perfect total return idea for the rest of 2025.
247wallst.com
- 2 weeks ago
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
seekingalpha.com
- 2 weeks ago
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA® as a first-line treatment option for patients with active psoriatic arthritis SPRING HOUSE, Pa. , April 4, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1 TREMFYA® is the first and only fully-human, dual-acting monoclonal antibody approved to treat PsA that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
prnewswire.com
- 2 weeks ago
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Both JNJ & PFE expect their sales and profits to improve in 2025.
zacks.com
- 2 weeks ago
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.
zacks.com
- 2 weeks ago
Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.
The Nasdaq Composite (^IXIC 0.87%) and the S&P 500 (^GSPC 0.67%) sank, shifting in and out of correction territory in the first quarter of the year for one big reason: investors have been worried about the economy. President Donald Trump is putting tariffs on imports, and economists predict this could lead to higher inflation and a slowdown in growth.
fool.com
- 2 weeks ago
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launched Cash runway extended into mid-2026 and reduction of operational cash burn expected beyond mid-2026 with €49.7 million in cash and cash equivalents as of December 31, 2024 Clinical data readouts in 2025 from Phase 1 and 2 studies in RM-HNSCC, pancreatic cancer, NSCLC amenable to re-irradiation, melanoma and esophageal cancer Conference call and webcast scheduled for April 3, 2025 at 8:00 A.M. EDT / 2:00 P.M.
globenewswire.com
- 2 weeks ago
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.
benzinga.com
- 2 weeks ago
8. Profile
Summary
Johnson & Johnson JNJ
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 363 B
Dividend Yield
0.86%
Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Contact
One Johnson & Johnson Plaza, New Brunswick, NJ, 08933
https://www.jnj.com
IPO
Date
Jan. 2, 1943
Employees
138100
Officers
Mr. Joseph J. Wolk CPA
Executive Vice President & Chief Financial Officer
Mr. Timothy Schmid
Executive Vice President & Worldwide Chairman of MedTech
Dr. John C. Reed M.D., Ph.D.
Executive Vice President of Innovative Medicine, R&D
Mr. Robert J. Decker Jr.
Controller & Chief Accounting Officer
Ms. Elizabeth Forminard J.D.
Executive Vice President & Chief Legal Officer
Mr. Dirk Brinckman
Chief Compliance Officer
Ms. Jessica Moore
Vice President of Investor Relations
Ms. Jennifer L. Taubert
Executive Vice President & Worldwide Chairman of Innovative Medicine
Mr. James Swanson
Executive Vice President & Chief Information Officer
Mr. Joaquin Duato
Chief Executive Officer & Chairman